May 2011 Blog Posts (45)

Are Mobile Phones Carcinogenic?

In a presentation earlier today, the WHO (World Health Organization) and the International Agency for Research on Cancer (IARC) has classified radiofrequency electromagnetic fields as possibly carcinogenic to humans (Group 2B), based on an increased risk for glioma, a malignant type of brain cancer [1], associated with wireless phone use.

Mobile or cellular phones are now an integral part of how we communicate. In many countries, more than half the population… Continue

Added by Peter Hofland, PhD on May 31, 2011 at 10:30am — No Comments

Study Shows that Vitamin E Tocotrienol May Increase Cancer Cell Apoptosis Without Toxicity

Preliminary results from a phase I clinical trial ( in patients with resectable pancreatic cancer shows that Vitamin E (delta-tocotrienol/Natural e3; Davos Life Science) may inhibit the growth and survival of various types of cancer cells.

Tocotrienols are highly potent members of the Vitamin E family. This clinical trial revealed that Natural e3,the brand name for DavosLife tocotrienols, was able to… Continue

Added by Peter Hofland, PhD on May 30, 2011 at 6:30am — No Comments

New Molecular Pathway Has Possible Implications for Cancer Treatment

Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina – a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.

The researchers report that myeloid cells, blood cells involved in the immune system, use this molecular pathway to guide… Continue

Added by Peter Hofland, PhD on May 29, 2011 at 10:00am — No Comments

Apricoxib Reverses a Key Process for Cancer Progression and Metastasis

Apricoxib (Capoxigem® also known as TG01; Tragara Pharmaceuticals, Inc), is an oral, once-daily selective COX-2 inhibitor being evaluated separately for the treatment of inflammation-related pain and cancer, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors.

These data results were presented at the 2011 American Society for… Continue

Added by Peter Hofland, PhD on May 26, 2011 at 10:30am — No Comments

Abiraterone Significantly Improves OS in Metastatic Castration-Resistant Prostate Cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM- New England Journal of Medicine, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with abiraterone acetate (Zytiga™,… Continue

Added by Peter Hofland, PhD on May 25, 2011 at 2:30pm — No Comments

Eribulin Treatment for Locally Advanced or Metastatic Breast Cancer Launched in UK

Eribulin (Halaven™, Eisai Inc), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease is launched today in the United Kingdom. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for… Continue

Added by Peter Hofland, PhD on May 24, 2011 at 4:30pm — No Comments

Improving Ovarian Cancer Detection: Second Study Showcases Role of OVA1 vs. CA 125

A paper published in the June 2011 issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone. The study is the second published online this month in the journal, which is the… Continue

Added by Peter Hofland, PhD on May 24, 2011 at 6:30am — No Comments

U.S. Food and Drug Administration Approves Sunitinib to Treat Pancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration earlier today approved Sunitinib (Sutent®, Pfizer) for the treatment of advanced pancreatic neuroendocrine tumors located in the pancreas that cannot be removed by surgery.

Neuroendocrine tumors found in the pancreas are generally slower growing and less aggressive than the more common form of pancreatic cancer. It is estimated that there are fewer than 1,000 new cases in the United States each year, or lesss than 5% of… Continue

Added by Peter Hofland, PhD on May 20, 2011 at 3:30pm — No Comments

Emerging Multi-Disciplinary Approaches to Prostate Cancer Care: Collaboration is Esstial

Urologists and radiation oncologists might serve prostate cancer patients better if they collaborated on multi-disciplinary approaches to treatment, rather than adopting an "either/or" perspective that often results in a choice between surgery, brachytherapy, external beam radiotherapy or stereotactic body radiotherapy, according to leading clinical experts presenting their work at the American Urological Association (AUA) Meeting in Washington, D.C. last week.… Continue

Added by Peter Hofland, PhD on May 20, 2011 at 5:30am — No Comments

Positive Opinion for Denosumab in Europe Based on Largest Clinical Trial in Bone Metastases

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of denosumab (XGEVA™, Amgen)for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid… Continue

Added by Peter Hofland, PhD on May 20, 2011 at 4:30am — No Comments

Anti-BAFF Monoclonal Antibody Shows 55% Response Rate in Previously-Treated Multiple Myeloma

Phase I data on LY2127399 (Eli Lilly and Company), a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib (Velcade®, Millenium Pharmaceuticals), in patients with previously-treated multiple myeloma.

Results from the Phase I study will be… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 6:30pm — No Comments

Carfilzomib Study Shows Overall Survival in Best Responding Patients Trending in Excess of 20 Months

Updated results from the Phase IIb 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma,shows that overall survival in "best responding patients" is trending in excess of 20 Months.

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 6:00pm — No Comments

Scientists Discover Novel Drug Target for Squamous Cell Carcinoma

Researchers at the Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma – the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., have found that a protein called alpha-catenin acts as a tumor suppressor and they also have unlocked the mechanism by which this protein controls cell proliferation.

The findings by… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 3:30pm — No Comments

Survivors of Childhood Cancer May be at Higher Risk for Future GI Compilations

A study led by researchers of University of California, San Francisco seems to suggest that survivors of childhood cancer may have a significantly higher risk of developing gastrointestinal (GI) complications—from mild to severe—later in life.

The findings underscore the need for childhood cancer survivors and their physicians to be aware of these risk factors to ensure patients’ ongoing health care needs… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 12:30pm — No Comments

Studies Confirm Improved Endoscopy Increases Detection of Esophageal Pre-Cancer by Over 40%

Two studies published in Digestive Diseases and Sciences have demonstrated that an improved method for performing the standard upper endoscopy examination done on over eight million Americans with heartburn each year increases the detection of pre-cancerous cells in the esophagus by over 40%.

Esophageal adenocarcinoma has increased by 600% over the last 25 years, making it the fastest growing form of cancer in the United States. It is also one of the most… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 11:30am — No Comments

Patent Office Grants Patent for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent for a platform of Heat Shock Protein 90 (Hsp90) inhibitors based on derivatives of the naturally occurring pochonin family, Pochonia chlamydospora.

The new patent directly benefits NexGenix Pharmaceuticals Inc., a privately-held company developing treatments for cancer, neurodegenerative diseases,… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 11:00am — No Comments

Phase II Clinical Data for JX-594 Shows Promising Survival Benefit in Advanced Liver Cancer

Preliminary data from a randomized dose-ranging Phase II trial of JX-594, which is being developed by Jennerex, Transgene (a member of the Institut Merieux Group), Green Cross Corporation, in patients with advanced liver cancer is showing a benefit in overall survival for the high dose group.

The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 9:30am — No Comments

Cixutumumab Shows Greatest Benefit in Adipocytic Sarcoma, Least in Rhabdomyosarcoma

A Phase II study with cixutumumab (Eli Lilly and Company) in five subtypes of sarcoma, a cancer that develops from connective tissues in the body, demonstrated that 57% of patients with a soft tissue sarcoma known as adipocytic sarcoma (a rare tumor that develops from fat cells) experienced stable disease. Results from the Phase II study will be presented on Monday, June 6 at 4:15 p.m. CDT during the Sarcoma Oral Abstract… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 5:30am — No Comments

Investigational Personalized Medicine Showed Promising Phase II Results in Lung Cancer

Final results from a randomized, multicenter, double-blind Phase II study with MetMAb, Genentech's investigational personalized medicine, in people with previously treated advanced non-small cell lung cancer (NSCLC)seems to indicate that the treatment may offer a beneficial treatment.

MetMAb is a unique monovalent or one-armed investigational antibody designed to target Met, a protein (or receptor) associated… Continue

Added by Peter Hofland, PhD on May 18, 2011 at 9:00pm — No Comments

Researchers Discovers Key to Fighting Drug-Resistant Leukemia

Doctors who treat children with acute lymphoblastic leukemia, the most common form of childhood cancer, are often baffled at how sometimes the cancer cells survive their best efforts and the most powerful modern cancer drugs.

Now a team of scientists led by researchers at the University of California, San Francisco (UCSF) have uncovered the basis for this drug resistance: BCL6, a protein that leukemia cells… Continue

Added by Peter Hofland, PhD on May 18, 2011 at 6:30pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+